Meeting
2022 ASCO Annual Meeting
Meta-analysis of randomized phase II-III trials evaluating triplet combinations of immunotherapy and targeted therapy for BRAF V600-mutant unresectable or metastatic melanoma.
Authors
Pier Francesco Ferrucci
European Institute of Oncology, Milan, Italy
Pier Francesco Ferrucci , Aurora Gaeta , Emilia Cocorocchio , Oriana D'Ecclesiis , Sara Gandini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9541)
DOI
10.1200/JCO.2022.40.16_suppl.9541
Abstract #
9541
Poster Bd #
134
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.
First Author: Ke Ji
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.
First Author: Qi Lin
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson